Abstract：
UNASSIGNED: Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections represent a leading cause of purulent skin and soft tissue infections in some geographical regions. Traditionally, \'old antibiotics\' such as trimethoprim-sulfamethoxazole, tetracyclines, clindamycin, chloramphenicol,vancomycin, and teicoplanin have been used to treat these infections, but these were often associated with low efficacy and excessive side effects and toxicity, especially nephrotoxicity. Along with the development of new compounds, the last decade has seen substantial improvements in the management of CA-MRSA infections.
UNASSIGNED: In this review, the authors discuss the current and emerging drug treatment strategies to tackle invasive CA-MRSA infections. Articles reported in this review were selected from through literature searches using the PubMed database.
UNASSIGNED: The availability of new drugs showing a potent in vitro activity against CA-MRSA represents a unique opportunity to face the threat of resistance while potentially reducing toxicity. All these compounds represent promising options to enhance our antibiotic armamentarium. However, data regarding the use of these new drugs in real-life studies are limited and their best placement in therapy and in terms of optimization of medical resources and balance of cost-effectiveness requires further investigation.
UNASSIGNED: In this review, the authors discuss the current and emerging drug treatment strategies to tackle invasive CA-MRSA infections. Articles reported in this review were selected from through literature searches using the PubMed database.
UNASSIGNED: The availability of new drugs showing a potent in vitro activity against CA-MRSA represents a unique opportunity to face the threat of resistance while potentially reducing toxicity. All these compounds represent promising options to enhance our antibiotic armamentarium. However, data regarding the use of these new drugs in real-life studies are limited and their best placement in therapy and in terms of optimization of medical resources and balance of cost-effectiveness requires further investigation.
摘要：
未经证实：：社区获得性耐甲氧西林金黄色葡萄球菌（CA-MRSA）感染是某些地理区域化脓性皮肤和软组织感染的主要原因。传统上,“旧抗生素”如甲氧苄啶-磺胺甲恶唑，四环素,克林霉素,氯霉素万古霉素和替考拉宁已被用于治疗这些感染，但这些往往与低疗效和过度的副作用和毒性有关，尤其是肾毒性.随着新化合物的发展,在过去的十年中,CA-MRSA感染的管理有了显著改善.
未经评估：在本次审查中，作者讨论了当前和新兴的应对侵袭性CA-MRSA感染的药物治疗策略.这篇综述中报告的文章是通过使用PubMed数据库进行文献检索来选择的。
UNASSIGNED：对CA-MRSA具有强大的体外活性的新药的可获得性代表了面对耐药性威胁的独特机会，同时可能降低毒性。所有这些化合物都代表了增强我们的抗生素武器库的有希望的选择。然而,关于这些新药在实际研究中使用的数据有限,它们在治疗方面以及在优化医疗资源和成本效益平衡方面的最佳位置需要进一步研究.
未经评估：在本次审查中，作者讨论了当前和新兴的应对侵袭性CA-MRSA感染的药物治疗策略.这篇综述中报告的文章是通过使用PubMed数据库进行文献检索来选择的。
UNASSIGNED：对CA-MRSA具有强大的体外活性的新药的可获得性代表了面对耐药性威胁的独特机会，同时可能降低毒性。所有这些化合物都代表了增强我们的抗生素武器库的有希望的选择。然而,关于这些新药在实际研究中使用的数据有限,它们在治疗方面以及在优化医疗资源和成本效益平衡方面的最佳位置需要进一步研究.
